Methods of use for IL-22 in the treatment of gastrointestinal graft vs. host disease
11564973 · 2023-01-31
Assignee
- Memorial Sloan-Kettering Cancer Center (New York, NY, US)
- EVIVE BIOTECHNOLOGY (SHANGHAI) LTD (Shanghai, CN)
Inventors
- Marcel Van Den Brink (New York, NY)
- Alan Hanash (New York, NY)
- Caroline Lindemans (Utrecht, NL)
- Tom Tang (Shanghai, CN)
Cpc classification
A61P1/00
HUMAN NECESSITIES
A61K2300/00
HUMAN NECESSITIES
A61K2300/00
HUMAN NECESSITIES
A61P37/06
HUMAN NECESSITIES
International classification
Abstract
The present invention provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stem Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.
Claims
1. A method for treating gastrointestinal graft versus host disease (GVHD) in a subject, the method comprising injecting the subject with a therapeutically effective amount of an interleukin-22 (IL-22), wherein the subject is an allo-hematopoietic stem cell transplant recipient.
2. The method of claim 1, wherein said IL-22 is recombinant IL-22.
3. The method of claim 2, wherein said recombinant IL-22is human IL-22.
4. The method of claim 1, wherein said IL-22 is in the form of an IL-22 dimer.
5. The method of claim 1, wherein the IL-22 is in the form of a fusion protein.
6. The method of claim 1, wherein said therapeutically effective amount of IL-22 is administered to the subject before transplant.
7. The method of claim 1, wherein said therapeutically effective amount of IL-22 is administered to the subject once onset of symptoms associated with injury to the gastrointestinal tract is observed.
8. The method of claim 1, wherein said therapeutically effective amount of IL-22 is administered to the subject from 1 day to 6 months following transplant.
9. The method of claim 1, wherein said therapeutically effective amount of IL-22 is administered to the subject beginning from 1 week to 4 months following transplant.
10. The method of claim 1, wherein said IL-22 is administered daily.
11. The method of claim 1, wherein said IL-22 comprises an IL-22-carrier fusion protein and the carrier comprises an Fc fragment selected from human IgG1, human IgG2, human IgG3, human IgG4, and human albumin.
12. The method of claim 11, wherein said IL-22comprises an IL-22-human IgG2 Fc fragment fusion protein.
13. The method of claim 12, wherein said IL-22is in the form of an IL-22dimer.
14. The method of claim 1, further comprising co-administering an immunosuppressive agent to the subject.
15. The method of claim 1, further comprising co-administering prednisone to the subject.
Description
BRIEF DESCRIPTIONS OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
DESCRIPTION OF THE INVENTION
(21) The present invention provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stem Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including affected cells such as hepatic, thymic, gastrointestinal, or other graft vs. host disease effects in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.
(22) The use of IL-22 was reported for use in the treatment of human diseases, such as pancreatic disease (for example, U.S. Pat. No. 6,551,799, herein incorporated by reference in its entirety) and viral hepatitis including for promoting hepatocyte survival and proliferation (for example, United States Patent Application 20130171100, herein incorporated by reference in its entirety). However IL-22 is not currently used as a treatment for human GVHD. In fact, the inventors found that treatment of GVHD with donor T cells engineered to produce IL-22 may cause undesirable effects such as increased skin GVHD.
(23) An IL-22 for use in practicing the method of the present invention can not only be generated using recombinant DNA technology, but can also be produced through fusion of heterologous polypeptides. A description of other methods, vectors and host cells for synthesis of an IL-22 for use in practicing the method of the present invention can be found in Gething et al., Nature, 293:620-625; Mantei et al., Nature, 281:40-46; EP117,060 and EP117,058. Recombinant IL-22, dimers and fusion proteins thereof are produced using methods known to those of skill in the art. For more details, see U.S. published application no. 2013/0171100, the contents of which are hereby incorporated by reference into the present disclosure.
(24) DNA sequences encoding an IL-22 dimer or fusion protein can be entirely synthesized artificially. Alternatively, DNA encoding IL-22 can be obtained by PCR amplification or synthesis and then joined together to form a DNA sequence encoding an IL-22 dimer.
(25) Briefly, suitable host cells are transformed or transfected with an IL-22 expression vector in accordance with known methods and subsequently grown under conditions known to those of skill in the art to promote growth; transfection techniques are described in greater detail in, for example, Molecular Cloning: a Laboratory Manual 3rd edition, J. F. Sambrook and D. W. Russell, ed. Cold Spring Harbor Laboratory Press 2001.
(26) Host cells suitable for expression of IL-22 are also known in the art and include invertebrate cells, such as insect cells, and mammalian cells. Suitable mammalian cells include Chinese Hamster Ovary (CHO), COS cells; in particular, SV40-transformed monkey kidney CV1 cell line (COS-7, ATCC CRL 1651); human embryo kidney cell line 293 (Graham et al., J. Gen Virol., 36:59 (1997)); CHO/−DHFR (Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); murine testis trophoblastic cells (TM4, Mather, Biol. Reprod., 23:243-251) (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); murine breast cancer cells (MMT 060562, ATCC CCL51).
(27) A nucleic acid comprising a nucleotide sequence encoding IL-22 can be inserted into a replicable vector for gene cloning or protein expression. Many vectors for protein expression are known in the art. Using these techniques, a nucleic acid sequence encoding IL-22 is inserted into an appropriate vector, which may further include any of the following: one or more signal sequences, an origin of replication, one or more reporter genes, an enhancer element, a promoter, and a transcription termination sequence.
(28) Methods of transfecting eukaryotic cells and transforming prokaryotic cells are also known to those of skill in the art, and may include the use of calcium chloride, calcium phosphate precipitation, lipofectamine or electroporation. One skilled in the art will be able to select a suitable method depending on the host cell selected.
(29) In one embodiment, a recombinant protein containing human IL-22 and produced in CHO cells in serum-free culture is used.
(30) A pharmaceutical composition for use in practicing the method of the present invention comprises a safe and effective amount of IL-22 or dimer, fusion protein or conjugate thereof and a pharmaceutically acceptable excipient or carrier. “Safe and effective amount” refers to an amount of a compound sufficient to significantly improve the condition of the patient in need thereof, without causing serious side-effects. In general, a pharmaceutical composition of IL-22 comprises 0.001-1,000 mg of IL-22 or its dimer per dose; in one embodiment, the pharmaceutical composition comprises 0.05-300 mg of IL-22 or its dimer per dose; in a further embodiment, the pharmaceutical composition comprises 0.5-200 mg of IL-22 or its dimer per dose.
(31) Pharmaceutically acceptable excipient or carrier are well known to those of skill in the art and may include cellulose and its derivatives (e.g. sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc), gelatin, speckstone, solid lubricating agent (e.g. stearic acid, magnesium stearate), calcium sulphate, plant oil (e.g. pea oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g. propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifier (e.g. Tween®), wetting agent (e.g sodium lauryl sulfate), colorant, flavoring agent, stabilizer, anti-oxidant, antiseptic, pyrogen-free water, etc.
(32) Routes of administration of IL-22, dimer, fusion protein or conjugate thereof includes oral administration, rectal administration, parenteral administration (intravenous, intramuscular, or subcutaneous), and partial administration.
(33) Allogeneic lymphocytes produce a strong graft-versus-leukemia (GVL) effect, but the beneficial effect is limited by graft-versus-host disease (GVHD). Depletion of T cells abrogated GVHD and GVL effects. Thus in IL-22 knock-out mouse and irradiated mouse models, IL-22 was produced by recipient-derived innate lymphoid cells (ILCs) and contemplated to provide a signal for epithelial recovery following experimental allogeneic hematopoietic cell transplantation (allo-HCT). These IL-22-deficient recipients demonstrated increased GVHD mortality and significantly worse loss of crypt base intestinal stem cells (ISCs) during GVHD. Paradoxically, GVHD also led to reduced gastrointestinal (GI) IL-22 levels in irradiated wild-type (WT) recipients due to the elimination of radioresistant intestinal cells (ILCs). Therefore the inventors were surprised to discover that IL-22 administration after allo-HCT negated (reduced) the effect of ILC elimination and further reduced GVHD pathology without impairing graft versus leukemia (GvL) responses.
(34) Benefits from using IL-22 compositions and methods comprising administering exogenous IL-22 of the present inventions include prophylactic protection and disease recovery of cells from GVHD including but not limited to cells of the small intestine, large intestine and liver.
(35) I. IL-22 Contributions to Intestinal Epithelium Cell Biology and GVHD.
(36) A. In Vivo Epithelial Maintenance Post-Transplant with and without GVHD.
(37) ISC and Paneth cell numbers persist post-transplant in the absence of GVHD however these numbers are reduced in GVHD (
(38) 1. Epithelial Renewal from Lgr5.sup.+ ISCs in Mice without GVHD.
(39) Measurement of the GI expression of molecules involved with ISC and Paneth cell function and kinetics of epithelial renewal. Using C57BL/6 (B6) background inducible Lgr5-LacZ lineage-tracing reporter mice developed in collaboration with colleagues at MSKCC. These mice express a β-galactosidase reporter molecule in Lgr5.sup.+ cells and in their progeny after treatment with tamoxifen. By treating recipient mice with tamoxifen on the day of transplant, this will allow for identification of cells in the crypt and villus regenerated from Lgr5.sup.+ ISCs post-transplant. Mice will be evaluated for the kinetics of epithelial regeneration from Lgr5.sup.+ cells in both the small and LI, and specific attention will be paid in the SI to the kinetics of Paneth cell renewal. Mice will be evaluated 5, 7, and 10 days after a) sublethal (550 cGy×1) and lethal (550 cGy×2) TBI in the absence of transplantation, after b) syngeneic (B6.fwdarw.B6) TCD BMT and after c) syngeneic T cell replete BMT to control for the effects of a) conditioning, b) cellular transplantation, and c) T cell transfer in impacting the kinetics of Paneth cell renewal from ISCs. In addition to lineage tracing, intestinal tissue will be harvested to measure RNA and protein expression of reported ISC genes (Lgr5, BMI-1, Hopx, mTert, Lrig1), Paneth cell genes involved with ISC function (Wnt3, EGF) by quantitative (q)PCR and western blot.
(40) 2. Epithelial Renewal, ISC Loss, and Paneth Cell Loss in Mice with GVHD.
(41) ISC and Paneth cell numbers are reduced in GVHD (
(42) Additionally, a temporal relationship between ISC loss and Paneth cell loss can be established by a time course study measuring ISC and Paneth cell numbers pre-transplant and 1, 3, 5, 7, 10, and 14 days post-BMT. This can be performed using Lgr5-LacZ stem-cell-only B6 reporter mice in which the β-galactosidase reporter molecule is expressed constitutively in Lgr5.sup.+ ISCs but not in their progeny. Lgr5.sup.+ ISCs can thus be counted with use of the reporter mice, and Paneth cells can be counted based on their characteristic histologic appearance after H&E staining. The earliest direct evidence of damage to the ISC compartment can be established in order to determine if ISC loss or Paneth cell loss occurs prior to the other in GVHD.
(43) As per the standard in murine models, TBI can be used as the method of pre-transplant conditioning. Additionally, evaluating GI epithelial renewal after treatment with non-myeloablative and ablative doses of chemotherapy may be done by evaluating for damage to the ISC compartment in patients having undergone clinical transplantation. The studies proposed emphasize Lgr5 expression as a marker of ISCs supported by the in vivo and ex vivo stem cell function of Lgr5.sup.+ cells. An alternative approach to stem cell phenotyping such as assessment of CD44.sup.+CD166.sup.+CD24.sup.− cells. Paneth cells make up the ISC niche in the SI but are largely absent in the LI, where Wnt signals are thought to be provided to the ISCs by niche-supporting kit.sup.+ cells. Therefore studies described herein and contemplated experiments are described herein to evaluate Paneth cells in the SI in GVHD. Additional studies on LI can be done by evaluating histologically for ckit.sup.+ LI niche cells.
(44) 3. Crypt Damage from GVHD with an In Vitro Model of ISC Function.
(45) ISCs post-BMT can be assessed by culturing intestinal organoids from transplanted mice. ISCs are reduced in GVHD through the use of genetic, phenotypic, and histologic markers (
(46) 4. An In Vitro System Modeling GVH Reactions Against the Stem Cell Niche.
(47) Gut GVHD manifests as intestinal disease however it apparently is the culmination of a systemic process involving T cell activation and migration. Indeed, the direct interactions occurring between allo T cells and recipient epithelial cells are not known. In order to visualize and efficiently test the mechanisms without limiting the invention to any particular mechanism of T cell-mediated damage to the stem cell niche, an in vitro system modeling gut GVHD with T cells directly interacting with GI epithelium cultured ex vivo can be tested. In preliminary studies, crypts cultured in vitro in the presence of allo T cells have a reduced capacity to grow into organoids.
(48) Therefore, murine SI and LI crypts can be isolated and cultured into organoids in the presence of allo T cells. Crypts are cultured with naive T cells, T cells pre-activated polyclonally (anti-CD3/anti-CD28), and T cells activated by APCs from crypt-background mice. Crypts can be assessed for their capacity to grow into organoids. This allows for discrimination between the requirement for pre-activation/antigen presentation and the ability of intestinal epithelium to activate T cells directly for its own elimination, as well as for differential capacities of CD4 and CD8 T cells. Organoids can be counted and measured for diameter and area by light microscopy. High resolution three-dimensional images can also be evaluated by confocal microscopy. In addition to culturing intact crypts, the above experiments can be repeated by culturing individual ISCs isolated from Lgr5-GFP reporter mice with allo T cells and measuring organoid formation as above. This also allows for direct imaging of ISCs in cultured organoids by expression of GFP, and also allows for evaluation of interactions between allo T cells and ISCs to determine if allo T cells can directly eliminate or impair the function of ISCs.
(49) Alternatively, single ISCs could be isolated by FACS based on the CD44.sup.+CD166.sup.+CD24.sup.−37 phenotype. Additionally, this would provide an added benefit of being able to culture cells from mice of additional backgrounds.
(50) B. Assess Stem Cell Elimination in GVHD.
(51) 1. Assess ISC and Niche Cell Expression of Death Receptors Before and after BMT.
(52) The loss of ISCs in GVHD may be due to the loss of their niche-providing Paneth cells, or the loss of Paneth cells may be due to the loss of their precursor ISCs. Alternatively, there may be comprehensive nonspecific damage to the ISC compartment mediated by allo T cells attacking both the ISCs and niche cells. We hypothesized that ISCs and/or Paneth cells will express death receptors that are involved in their immune-mediated elimination in GVHD.
(53) In this subaim we can isolate murine ISCs and Paneth cells from Lgr5-GFP reporter mice and phenotyope these cells by FACS for expression of potential death receptors involved in GVHD (Fas, TNFR, IFNγR, and DR5). Expression can be compared at baseline, after TCD BMT, and in mice with GVHD. ISCs and Paneth cells can be distinguished by GFP expression in ISCs, and the granular (sideward scatter high) CD24.sup.+ bright phenotype (see
(54) 2. Function of T Cell Cytotoxic Molecules in Damaging the ISC Compartment.
(55) T cell cytotoxic pathways may be involved in the damage of the ISC compartment during GVHD. We can test the ability of T cells deficient for cytotoxic pathways to damage ISCs and their niche in vivo and in vitro. SI and LI crypts can be cultured with allo T cells from mice deficient in secreted or cell surface death receptor ligands (FasL, TNFα, IFNγ, TRAIL) as well as perforin and evaluate the number and size of organoid development as described herein. T cells with impaired ability to damage crypts in vitro are then evaluated in vivo by performing allo BMT with deficient T cells and assessing histologically post-BMT for ISC and Paneth cell elimination. If the in vitro allo T cell/crypt culture system proves unreliable, effects of potential death ligands can be tested in traditional in vivo GVHD models.
(56) Utilizing cytotoxic-deficient T cells require primarily the use of B6 mice as the allo T cell source, preventing the use of B6 background Lgr5 reporter mice for in vivo readout of Lgr5 expression and for selection of individual ISCs for culture with deficient T cells. Therefore, neutralizing antibodies may be used to block cytotoxic pathways regardless of the T cell and crypt strains used, and may isolate ISCs by FACS based on CD44.sup.+CD166.sup.+CD24.sup.−37 phenotype and culturing them with B6 background deficient T cells.
(57) 3. Expression of ISC Molecules and Niche Molecules in Patients Post-BMT.
(58) Crypt apoptosis is a hallmark of GI GVHD, and we have observed deficiency of ISCs and Paneth cells in experimental GVHD models, and low Paneth cell counts are associated with increased non-relapse mortality in patients. However, specific damage to the ISC and niche cell compartment in clinical GVHD is poorly understood. Therefore, we can evaluate the expression of ISC-related molecules in BMT patients.
(59) In order to assess ISCs and their niche in clinical GVHD, we can evaluate mRNA and protein expression of ISC-related molecules in the GI tract of patients requiring endoscopy for evaluation of GI complaints post-transplant. Biopsy specimens for research purposes can be acquired under MSKCC IRB protocol from patients undergoing clinically indicated GI biopsies related to symptoms post-transplant. Samples are compared between patients found to have biopsy proven GI GVHD and those without GVHD, including patients having undergone TCD transplantation. Tissue specimens can be evaluated for expression of Lgr5, BMI-1, Hopx, mTert, Lrig1, Wnt3, and EGF as described above. In addition, given our findings of IL-23-dependent IL-22-mediated support of ISCs in experimental GVHD, we can evaluate the expression of IL-22 and IL-23 in biopsied samples as well. We can also perform IHC on these samples to identify IL-22R expression in human crypts. Finally, GI expression of the molecules listed above can be compared to their expression in peripheral blood drawn the day of endoscopy to evaluate correlation between gut and systemic expression.
(60) Biopsy specimens may also be evaluated by FACS to identify IL-22R expression on phenotypically identified ISCs and Paneth cells as described above with CD44, CD166, and CD24 staining. Alternatively, ISCs could be identified by in situ hybridization or IF for Lgr5.
(61) 4. Functional Damage to the ISC Compartment in Patients with GVHD.
(62) While ISC damage is thought to occur due to the crypt damage found in GI GVHD, and while there is data for ISC loss in mice with GVHD, this type of damage has not been directly demonstrated in patients. We contemplate that patients with GVHD will have fewer detectable ISCs than patients without GVHD.
(63) In order to assess the loss of ISCs in human patients with GVHD, SI and LI crypts can be isolated from patients undergoing clinically indicated endoscopies and biopsies for evaluation of GI symptoms post-transplant. Crypts isolated from patient biopsy specimens can then be cultured in vitro for organoid formation as described herein, comparing organoid generation from patients with or without GVHD, as well as comparing the stage of GVHD severity. As an alternative, we can also evaluate the loss of ISCs and niche cells by performing FACS of isolated cells for ISCs niche cells as described above. Additionally, normal GI tissue from the MSKCC Pathology department can therefore be evaluated as well to serve as a negative control for transplant-related effects on the ISC compartment.
(64) C. ISC-Supportive Strategies to Treat GVHD.
(65) We have identified that mice deficient for IL-22 have exacerbated ISC loss in GVHD and show herein that exogenous IL-22 administration increases ISC recovery. Therefore IL-22 can be used to serve as an ISC growth factor on organoids in vitro and as an epithelium-targeted GVHD treatment in mice with GVHD.
(66) 1. Effect of IL-22 on Organoids In Vitro.
(67) While IL-22 can maintain epithelial integrity after damage, the effect of IL-22 on the ISCs compartment is largely unknown. Our preliminary data indicates that IL-22R is expressed on ISCs (
(68) Effect of IL-22 on ISC function can be observed by culturing crypts and ISCs isolated as described above in the presence of 0.1-10 ng/ml rIL-22 starting day zero or day two of culture. IL-22 can also be added on day zero of culture and then removed from the culture media on day two. Organoids can be evaluated for size and number, and can also be evaluated by confocal microscopy for high-resolution images. After identifying optimal IL-22 culture conditions, we can culture organoids from Lgr5-GFP reporter mice with IL-22 then can evaluate for JAK/STAT signaling, proliferation, and expression of anti-apoptotic molecules by FACS. We also evaluated the effect of IL-22 on human crypts isolated from transplant patients.
(69) To begin evaluating for a role of IL-22 in regulation of the ISC compartment, murine small intestine (SI) crypts were isolated and cultured with EGF, Noggin, and R-spondin-1 (ENR) in the presence or absence of recombinant murine (rm)IL-22. Culturing crypts with rmIL-22 for seven days led to the growth of substantially larger organoids than those cultured with ENR alone (
(70) In addition to the augmented size of SI organoids, culture with IL-22 led to increased perimeter size and surface area of large intestine (LI) organoids (
(71) Group 3 TLCs are a major source of GI IL-22 in colitis, during enteric bacterial infection, and after BMT13-16. To determine if ILCs could regulate the ISC compartment and augment organoid growth, CD45+CD11b−CD11c−B220−CD3−CD90+ cells were sorted from intestinal lamina propria and cultured in Matrigel with freshly isolated SI crypts. ENR provided basic signals for organoid development, and a cocktail of cytokines including IL-23 was included for activation of TLCs. The presence of ILC activation cytokines alone had no effect on the growth of SI organoids. However, co-culture with ILCs led to increased organoid size (
(72) We next evaluated intracellular signaling activated by IL-22 within organoids. Although Wnt/β-catenin signaling is essential for ISC maintenance and organoid function ex vivo12, we found no evidence of enhanced production of molecules in the Wnt/β-catenin pathway within SI organoids cultured with IL-22, including no difference in expression of Wnt3, β-catenin, or Axin 2 (
(73) Little is known about JAK/STAT signaling within ISCs, although it has been reported that STAT3 may be important for ISC maintenance. We evaluated STAT3 signaling in SI organoids by phosflow and found that IL-22 led to phosphorylation of STAT3 Y705 (
(74) To determine if IL-22-dependent signaling in ISCs was functionally significant, we isolated Lgr5-GFP ISCs by fluorescence-activated cell sorting, and cultured single ISCs in Matrigel under standard conditions +/−IL-22. IL-22 led to significantly greater budding of early organoids after just four days in culture (
(75) As IL-22 led to increased organoid size, crypt budding, and STAT3 activation, we next sought to determine if this resulted in expansion of ISCs. We evaluated 5-ethynyl-2′-deoxyuridine (EdU) incorporation into organoids cultured with IL-22, as a short one-hour incubation of organoids with EdU has been shown to mark the S phase of fast-cycling CBC cells. IL-22 led to increased organoid EdU incorporation, indicating augmented proliferation within organoid crypts (
(76) FACS of cultured organoids purified from semi-solid media may have high background staining and may be difficult to interpret. In that case, organoids grown +/−IL-22 could be evaluated for proliferation and apoptosis by gene expression. In addition, microarray could be performed to globally evaluate crypt gene expression after IL-22 treatment.
(77) 2. Effect of IL-22 Administration on GVHD In Vivo.
(78) ISC biology proposed here develops a therapeutic modality to promote ISC function as an epithelium-targeted treatment for GVHD. Preliminary data described herein indicated that IL-22 production is impaired in GVHD due to the loss of IL-22-producing ILCs (
(79) We acquired a clinical grade human IL-22 dimer, F-652 (Evive Biotechnology (Shanghai) Ltd.), that cross-reacts with mouse IL-22R. Potential benefits of using this dimer, formed by two IL-22 monomers with Fc fragments via coupling of the Fc fragments, include use in clinical translation along with the benefit of the increased half-life if the IL-22 dimer compared to the recombinant IL-22, as described in U.S. Patent Appln. No. US2003/0100076, herein incorporated by reference in its entirety. We observed that F-652 was able to augment the growth of organoids in vitro (
(80) Allo-BMT can be performed as described above with Lgr5-LacZ reporter mice as recipients with both miHA and MHC mismatched models. Recipients can be treated pre-transplant and/or post-transplant with F-652 human IL-22 dimer and then sacrificed three weeks post-BMT to evaluate for GVHD pathology and ISC recovery. Allo-BMT with WT recipients can be performed and evaluated for survival differences in GVHD after F-652 treatment, and we can transplant mice in the presence of hematologic malignancies (such as in
(81) Preliminary data indicated that IL-22 may be reducing GVHD by directly stimulating ISC proliferation, and not by indirectly supporting ISCs by targeting the ISC-supporting Paneth cells (
(82) Reduced numbers of ISCs and niche-forming Paneth cells have recently been described in mice with GVHD. Given the stable alloreactive immunity after IL-22 treatment, we next evaluated the effect of IL-22 on the ISC compartment directly. We performed LP.fwdarw.B6 allogeneic BMT using Lgr5-LacZ recipients to identify ISCs post-transplant. BMT with T cells led to GVHD and significant loss of Lgr5+SI ISCs three weeks post-BMT (
(83) To understand how IL-22 administration could lead to increased numbers of ISCs in mice with GVHD, we transplanted B6 Lgr5-GFP reporter mice with LP marrow and T cells. Recipients were treated daily for seven days with rmIL-22 or PBS IP, and then SI crypts were isolated and evaluated by flow cytometry on day 14 post-BMT. Consistent with our ex vivo findings of increased organoid growth and EdU incorporation, Lgr5-GFP+ cells expressed increased Ki-67 after in vivo treatment with rmIL-22, indicating that the treatment augmented proliferation of the ISC pool (
(84) Paneth cells provide a supportive microenvironment for Lgr5+ISCs through delivery of Wnt and EGF signals to CBC stem cells. Additionally, IL-22 is thought to regulate Paneth cells and their production of innate antimicrobial molecules. We thus hypothesized that IL-22 administration could support ISC recovery post-BMT by improving the stem cell niche and augmenting Paneth cell-mediated support of ISCs. Consistent with studies of clinical GVHD and MHC-mismatched experimental models, LP.fwdarw.B6 minor antigen-mismatched BMT led to a reduction in Paneth cells three weeks post-transplant (
(85) Although IL-22 did not improve the niche-supporting capacity of Paneth cells, it remained possible that IL-22 could indirectly promote ISC proliferation in vivo by augmenting stroma-mediated stem cell support. It was recently shown that stromal cells can contribute to maintenance of the ISC niche, supporting normal intestinal homeostasis in vivo through production of Wnts and R-spondin-3, even in the absence of Paneth cell-derived Wnts33. However, we found no evidence for increased niche-derived Wnt signals after IL-22 treatment in vivo (
(86) Finally, given the clear effect of IL-22 in augmenting ISC regeneration and epithelial recovery in vivo, we evaluated the impact of IL-22 administration on systemic GVHD. It has been proposed that GI damage may be central to the pathogenesis of systemic GVHD. Consistent with a recent report where IL-22 was administered peri-transplant, we found no improvement in GVHD mortality following F-652 administration to recipients of MHC-mismatched BMT (not shown). However, we found that an early intervention model with F-652 starting one week after MHC-matched allogeneic BMT led to reduced systemic signs of GVHD and significantly improved overall survival (
(87) II. IL-22+ Lactobacilli as a Novel Targeted Therapeutic Approach for Prevention and Treatment of Clinical GVHD.
(88) As an alternative approach to pharmacologic reintroduction of IL-22, i.e. exogenous IL-22, we developed a probiotic strategy with lactobacillus that constitutively produces IL-22, see below and in the Experimental section. Thus in one embodiment, exogenous IL-22 is used in methods of treatment along with a probiotic. In another embodiment, exogenous IL-22 is administered to patients as described herein, along with a probiotic. In preliminary studies, administration of a probiotic of the present inventions to mice post-BMT appeared to reduce systemic GVHD.
(89) Therefore, IL-22+lactobacilli are contemplated as a novel targeted therapeutic approach for prevention of clinical GVHD and transplant-related tissue damage without limiting essential donor immune functions. Lactobacillus administration was shown to reduce experimental GVHD. Moreover, Lactobacillus paracasei is a normal constituent of human GI flora. Therefore the inventors contemplated the use of engineered Lactobacillus paracasei to deliver therapeutic doses of exogenous IL-22 for providing additional therapeutic benefits. Indeed, the following describes making and using IL-22 expressing bacteria along with preliminary experiments showing the results of reduced endogenous IL-22 production, section A. Methods and materials for making and using IL-22+lactobacilli including contemplative experiments are described in section B.
(90) A. HCT in Mice Expressing Reduced Endogenous IL-22.
(91) IL-22−/− KO recipients of HCT demonstrated increased mortality following both minor (
(92) Expression of IL-22 was found within the GI tract (
(93) Although host IL-22 deficiency increased GVHD (
(94) Immunohistochemistry (IHC) and immunofluorescence (IF) indicated IL-22R expression within intestinal crypts where the ISC niche is located (
(95) Therefore, GI damage led to induction of IL-23. IL-23 in turn can stimulate IL-22 production by ILC. This endogenous IL-22 protected the epithelium and the stem/progenitor cell compartment from inflammatory tissue damage. However, IL-22-producing ILC necessary for limiting tissue damage were lost during GVHD. As shown herein, administration of rIL-22 post HCT by intraperitoneal injection (for example, 4 ug/mouse daily) reversed the effects of ILC depletion and loss of IL-22 in GVHD pathology within the intestines as well as reduce apoptosis within intestinal crypts where the ISC/progenitor compartment is located (
(96) B. IL22+ Lactobacilli Treatment of GVHD.
(97) As described herein, after discovering that IL-22 deficiency leads to increased GVHD (
(98) In contrast, mice receiving lacto-22s or lacto-22a did not have significantly different mortality compared to mice transplanted without T cells. Furthermore, recipients of lacto-22s had significantly reduced clinical scores of GVHD, an assessment encompassing weight, fur quality, skin integrity, posture, and activity. While the change in weights of mice post-HCT can serve as a surrogate measure for GI GVHD, the systemic nature of these findings suggest that GI protection may be central to preventing systemic disease from GVHD.
(99) T cell depleted MHC matched allo-HCT was done as described above and mice were gavaged daily with lacto-WT, lacto-22s, and lacto-22a. Additionally, PCR for IL-22 is contemplated to be performed from recipient intestinal pellets to confirm presence of lacto-22 in the GI tract. MHC matched allo-HCT model most closely matches transplants that are performed clinically in human patients, where transplant donors are selected preferentially based on MHC matching to the recipient. In addition, experiments will be performed where mice will be sacrificed three weeks post-HCT to assess GVHD pathology and crypt apoptosis. In order to directly test the effect of lacto-22 on ISC, transplants as described above will be made with Lgr5-LacZ mice as recipients to assess the elimination of Lgr5′ ISC. Lacto-22 administration will be compared to rIL-22 for safety and reduction of GI pathology and mortality.
(100) Effects of IL-22 Produced by Lactobacillus on Intestinal Epithelium.
(101) Lacto-22 treatment of mice appeared to reduce GVHD mortality and symptoms. Therefore experiments are contemplated for effects on lacto-22 on intestinal epithelium by measuring systemic IL-22 in serum by ELISA. ELISA for IL-22 from homogenized tissue samples and assess downstream effects of IL-22 within the tissues by measuring intestinal phosphorylated STAT-3 by IHC and western blot. Finally, electron microscopy will be performed in an attempt to image if gavaged lactobacillus can penetrate into the epithelium. Alternatively, lactobacillus from the blood or tissue homogenates of transplanted mice will be cultured to determine if the bacteria are entering the systemic circulation. Lacto-22 carries a resistance gene for chloramphenicol to facilitate proper identification of lacto-22 under culture conditions.
(102) Effects of Lacto-22 on Donor T Cells and Recipient Flora.
(103) B6 HCT into BALB/c allo-HCT mice will be treated daily with a gavage of lacto-WT and lacto-22 as described above. Donor marrow will be derived from CD45.1 B6 and T cells will be derived from WT B6 (CD45.2+) to facilitate identification of donor T cells by flow cytometry. Donor T cell expansion in the spleen, mesenteric lymph nodes, and intestinal lamina propria eill be measured including the effector-to-regulatory T cell ratio. We will also assess donor T cell expression of activation/memory markers and cytotoxic effector molecules including Fas ligand. Serum and intracellular cytokine expression for inflammatory cytokines, and we will measure by PCR epithelial tissue expression of innate antimicrobial molecules induced by IL-22 (Reg3γ and Reg3β). As antimicrobials downstream of IL-22 may have effects on the flora and the presence of administered lactobacilli may themselves have profound effects on the flora, we will perform 16S rDNA sequencing as we have recently published in order to assess diversity of the microbiota after administration of lacto-22.
(104) Effect of Lacto-22 on GVL.
(105) Given the limitation of IL-22R expression to non-hematopoietic cells, lacto-22 should not suppress GVL or promote hematopoietic tumor growth. This line of experimentation is important for potential clinical translation of lacto-22. Preliminary experiments with IL-22 KO donor T cells or with WT T cells after rIL-22 treatment in vivo showed no observable differences in GVL capacity (
(106) While experimentally efficient, HCT with tumor cell lines represents a model with questionable direct correlation to clinical transplant with de novo malignancies. We have thus developed a model of experimental GVL (
EXPERIMENTAL
(107) The following examples are provided in order to demonstrate and further illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.
(108) In the experimental disclosure which follows, the following abbreviations apply: N (normal); M (molar); mM (millimolar); μM (micromolar); mol (moles); mmol (millimoles); μmol (micromoles); mnol (nanomoles); pmol (picomoles); g (grams); mg (milligrams); μg (micrograms); ng (nanograms); 1 or L (liters); ml (milliliters); μl (microliters); cm (centimeters); mm (millimeters); μm (micrometers); nm (nanometers); .degree. C. (degrees Centigrade); Gy (gray) and cGy (centigray).
Example I
(109) This Example describes materials and methods used herein.
Materials and Methods
(110) C57BL/6 (CD45.2 B6, H-2b), B6.SJL-Ptprca Pepcb/BoyJ (CD45.1 B6 congenic, H-2b), Il12b−/−B6, BALB/c (H-2d), and LP (H-2b) mice were obtained from the Jackson Laboratory. B6 and BALB/c Il22−/−mice were provided by Genentech, as was anti-IL-22 neutralizing antibody 8E11. Lgr5-LacZ and Lgr5-GFP B6 mice were provided by H. Clevers (Barker et al., 2007). BMT procedure was performed as previously described (Petrovic et al., 2004), with 850 cGy split-dosed lethal irradiation of BALB/c hosts receivingbone marrow (5×106), T cell-depleted with anti-Thy-1.2 and low-TOX-Mrabbit complement (Cedarlane Laboratories), or performed with 1100 cGysplit-dosed lethal irradiation of B6 hosts receiving T cell-depleted bonemarrow (5×106) as well. Donor T cells (typically 1×106B6 or 4×106 LP, unless otherwise specified) were prepared for transplantation by harvesting donor splenocytes and enriching for T cells by either nylon wool passage (routinely >70% T cell purity) or by Miltenyi MACS purification of CD5 (routinely >90% purity). Recipient mice were monitored for survival and clinical GVHD symptoms and were sacrificed for blinded histopathologic and flowcytometric analysis as previously described (Petrovic et al., 2004). Forchimeric experiments, CD45.1 B6 congenic mice were lethally irradiated andreconstituted with either wild-type or Il22−/−CD45.2 marrow. Three months later, donor reconstitution was confirmed by FACS of peripheral blood for CD45.1 versus CD45.2, and chimeric mice were irradiated again (900 cGy,split dose) and transplanted with LP marrow (10×106) and T cells (3×106). Mice.
(111) C57BL/6 (CD45.2 B6, H-2b) and LP (H-2b) mice were obtained from Jackson Laboratory (Bar Harbor, USA). B6 Lgr5-LacZ and B6 lgr5-gfp-ires-CreERT2 (Lgr5-GFP) mice were kindly provided by H. Clevers. Mice were housed in micro-isolator cages, five per cage, in MSKCC pathogen-free facilities and received standard chow and autoclaved sterile drinking water. Mouse maintenance and procedures were done in accordance with the institutional protocol guideline of the Memorial Sloan Kettering Cancer Center (MSKCC) Institutional Animal Care and Use Committee.
(112) Crypt Isolation and Cell Dissociation.
(113) Isolation of intestinal crypts and the dissociation of cells for flow cytometry analysis were largely preformed as previously described. Briefly, after euthanizing the mice through CO.sub.2 asphyxiation, and harvesting small and large intestine, the organs were opened longitudinally and washed. Small intestine has been incubated in ethylenediamine-tetraacetatic acid (EDTA) 5 mM for 60 min or 10 mM for 25 min (4° C.) to dissociate the crypts; large intestine was incubated in Collagenase Type 4 (Worthington) for 30 min (37° C.). The supernatant containing crypts was collected. For crypt disaggregation into single cells, the crypt pellet was further incubated in 1× trypLE express (Gibco, Life technologies) complemented with 0.8 KU/ml DNase1 (Roche). Isolated crypts for RNA extraction were resuspended in 1 ml of Trizol (invitrogen) and stored at −80° C.
(114) Organoid Culture.
(115) 400 crypts per well were suspended in liquefied growth factor reduced Matrigel (Corning) (25% Advanced DMEM/F12 medium (Gibco); 75% growth factor reduced Matrigel) at 4° C. Then, they were plated in pre-warmed delta-surface Nunc 24-well plates in 50 μL drops for small intestine, 30 ul drops for Large intestine, each containing approximately 100-500 crypts. After the Matrigel drops polymerized, 500 ul complete crypt culture medium was added to small intestine crypt cultures (ENR-medium: advanced DMEM/F12 (Sigma), 2 mM L-glutamine (Sigma), 10 mM HEPES (Sigma), 100 U/ml penicillin/100 μg/ml streptomycin (Sigma), 1 mM N-acetyl cysteine (Sigma), 1× B27 supplement (Invitrogen,), 1×N2 supplement (Invitrogen), 50 ng/ml mEGF (Peprotech), 100 ng/ml mNoggin (Peprotech) and 10% human R-spondin-1 conditioned medium of hR-spondin-1-transfected HEK 293T cells. In some experiments evaluating budding, the concentration of hR-spondin-1 was lowered to 1.25-5%. Large intestine crypts were cultured in WENR-medium containing 50% of Wnt3a conditioned medium in addition to the aforementioned proteins and 1% Bovine serum Albumin (Sigma). For large intestine cultures 10 uM SB202190 (Sigma, Cat.nr.S7067) and ALK5 inhibitor (A83-01, Tocris) were added to the WENR. All plates were incubated at 37° C./5% CO.sub.2 and the media was replaced every 2-3 days. Control wells were left untreated, and where applicable, treatment wells received different concentrations of recombinant murine (rm)IL-22 (Genscript) along with medium changes. Crypts were passaged at day seven by mechanically disrupting them with a seropipet, washing away the Matrigel by spinning down the crypts in excess medium, and replating them after reconstitution of the pellet in liquefied Matrigel. We also tested the effects of F-652, a recombinant human IL-22 dimer molecule provided by Evive Biotechnology (Shanghai) Ltd, China. In some experiments, organoids were cultured from crypts in the presence of Stattic (STAT three inhibitory compound, 6-Nitrobenzo[b]thiophene 1,1-dioxide; Tocris Bioscience).
(116) Intestinal stem cells were isolated from LgR5-GFP mice using a modified crypt isolation protocol with 20 minutes of 30 mM EDTA3,4 followed by several strainer steps and a 5 min incubation with TrypLE and 0.8 under min to minute vortexing to make a single cells suspension. The Lgr5-GFPhigh cells were isolated by fluorescence-activated cell sorting. 5000 TLCs were plated in 30 uL growth factor reduced Matrigel drops and cultured in WENR containing 10 uM rho-kinase inhibitor Y-27632 in the medium and 1 uM Jagged 1 notch ligand (Anaspec) and Rhokinase inhibitor (10 uM) in the Matrigel. ISC cultures were cultured without Wnt from D4.
(117) For innate lymphoid cell (LC) co-culture experiments, intestinal lymphocytes were isolated from the small intestine lamina propria. After washing small intestine fragments, 20 ml/mouse prewarmed EDTA/IEL solution (1×PBS with 5% FBS, 10 mM Hepes Buffer, 1% Pen/strep Corning, 1% L-glutamine (Gibco), 1 mM EDTA and 1 mM DTT was added, followed by placing the samples in a 37° C. shaker for 15 minutes. The samples were strained (100 uM) and put in a Collagenase solution (RPMI 1640, 5% FCS, 10 mM Hepes, 1% PS, 1% Glutamine and 1 mg/ml Collagenase A (Roche) and 1 u/ml DNAse 1 (Roche) and left for 10 minutes in the 37° C. shaker. Afterwards, the samples were centrifugated at 1500 rpm for five minutes and washed with RPMI solution without enzymes. After several washes, the cell suspension was transferred into a 40% Percoll solution (Percoll in RPMI), which is overlaid on a 80% Percoll solution. After spinning the interface containing the lamina propria mononuclear cells was aspirated and washed in medium. Then the cell suspension was stained with extracellular markers and Topro 3 for viability. ILCs were selected and sorted as Topro3−, B220−, CD11b−, CD11c−, CD45+, CD3+ and CD90.2+ cells. 1000 ILCs were plated with 400 crypts in the Matrigel per well. For co-cultures with ILCs rmIL-2 (1000 u/ml), rmIL-15 (10 ng/ml) and rmIL-7 (50 ng/ml) and rmIL-23 (50 ng/ml) were added to the ENR medium. Cocultures were compared to crypts cultured in the cytokine containing ENR without the ILCs present.
(118) Bone Marrow Transplantation.
(119) Bone marrow transplantation (BMT) procedures were performed as previously described. A minor histocompatibility antigen-mismatched BMT model (LP.fwdarw.B6, H-2.sup.b.fwdarw.H-2.sup.b) was utilized. Female B6 WT mice were typically used as recipients for transplantation at an age of 8 to 10 weeks. Recipient mice received 1100 cGy of split-dosed lethal irradiation (550 cGy×2) 3-4 hours apart to reduce gastrointestinal toxicity. To obtain LP bone marrow cells from euthanized donor mice, the femur and tibia were harvested aseptically and the bone marrow canals washed out with sterile medium. Bone marrow cells were depleted of T cells by incubation with anti-Thy 1.2 and low-TOX-M rabbit complement (Cedarlane Laboratories). The T cell-depleted bone marrow was analyzed for purity by quantification of the remaining contaminating T cells. The contamination of T cells usually was about 0.2% of all leukocytes after a single round of complement depletion and 0.1% after a second round. The LP donor T cells were prepared by harvesting splenocytes aseptically from euthanized donor mice. T cells were purified using positive selection with CD5 magnetic Microbeads with the MACS system (Miltenyi Biotec). The purity of the cells was determined by flow cytometry and was routinely approximately 90%. Recipients typically received 5×106 bone marrow cells with or without 4×106 T cells per mouse unless otherwise specified via tail vein injection.
(120) Mice were monitored daily for survival and weekly for graft vs. host disease (GVHD) scores with an established clinical GVHD scoring system (including weight, posture, activity, fur ruffling, and skin integrity) as previously described6. A clinical GVHD index with a maximum possible score of ten was then generated. Mice with a score of five or greater were considered moribund and euthanized by CO.sub.2 asphyxia.
(121) Cytokine Administration.
(122) Recombinant murine IL-22 was purchased from GenScript and reconstituted as described by the manufacturer to a concentration of 40 g IL-22/1000 ul phosphate-buffered saline (PBS). Each mouse was treated with either 100 μl PBS or 100 μl PBS containing 4 g recombinant mouse IL-22 daily via intrapertitoneal injection. IL-22 administration was started day seven post-BMT. This schedule was based on the results of rIL-22 pharmacokinetics tested in untransplanted mice. For F-652 administration in vivo, mice were treated with PBS or 100 μg/kg F-652 subcutaneously every other day for ten weeks starting day seven post-BMT.
(123) Histopathologic Analysis of GVHD Target Organs.
(124) Mice were euthanized for organ analysis at D21 post-BMT using CO.sub.2 asphyxiation. For histopathological analysis of GVHD, the small and large intestines were formalin-preserved, paraffin-embedded, sectioned, and stained with hematoxylin and eosin (H&E). A semi quantitative score consisting of 19 different parameters associated with GVHD was calculated, as described previously.
(125) Paneth Cell and Stem Cell Histologic Staining.
(126) For staining of Paneth cells, intestines were harvested from euthanized mice and formalin-preserved, paraffin-embedded, sectioned, and stained with a polyclonal rabbit anti-human lysozyme 3.2.1.17 (Dakocytomaion). For evaluation of stem cell numbers, small intestines from Lgr5-LacZ recipient mice that were transplanted with LP bone marrow (and T cells where applicable) were harvested. β-galactosidase (LacZ) staining was preformed as previously described by Barker et al. Washed 2.5 cm sized small intestine fragments were incubated with an ice-cold fixative, consisting of 1% formaldehyde, 0.02% NP40 and 0.2% gluteraldehyde. After removing the fixative, organs were stained for the presence of LacZ. Then the organs were formalin-preserved, paraffin-embedded, sectioned, and counterstained with Nuclear Fast Red (Vector).
(127) Cytokine Multiplex Assay.
(128) Spleen and small intestine were harvested from euthanized BMT recipients. Then organs were homogenized, spun down and the supernatant stored at −20° C. until used for cytokine analysis. The cytokine multiplex assays were performed on thawed samples with the mouse Th1/Th2/Th17/Th22 13plex FlowCytomix Multiplex kit (eBioscience) and performed according to the manufacturer's protocol.
(129) Flow Cytometry.
(130) For the in vivo experiments evaluating the effect of IL-22, lymphoid organs were harvested from euthanized mice and processed into single cell suspension. Cells were stained with the appropriate mixture of antibodies. For analysis of intracellular molecules an eBioscience Fixation/Permeabilization kit was used per the manufacturer's protocol for intracellular staining. After thorough washing, the cells were stained with intracellular and extracellular antibodies simultaneously. Fluorochrome-labeled antibodies for intracellular and extracellular staining were purchased from BD Pharmingen (CD4, CD8, CD24, CD25, CD45, α4β7, Ki-67, and P-STAT3 Y705), eBioscience (Foxp3), R&D (IL-22R), and Invitrogen (GFP). DAPI and Fixable Live/Dead Cell Stain Kits (Invitrogen) were used for viability staining. Paneth cells were identified based on bright CD24 staining and side scatter granularity as described by Sato et al. 7.
(131) For flow cytometry of small intestine organoid cells, the ENR medium was removed and the crypts and Matrigel were resuspended in TrypLE for approximately eight minutes. After vigorously pipetting through a p200 pipette causing mechanical disruption, the crypt suspension was washed with 10 ml of DMEM/F12 medium containing 10% FBS and 0.8 KU/ml DNase1. Suspensions were then evaluated for percentage of GFP+ cells. Where applicable, the cells were directly stained or first fixed and permeabilized depending on the extra- or intracellular location of the target protein. All stainings with live cells were performed in PBS without Mg2+ and Ca2+ with 0.5% BSA. For 5-ethynyl-2′-deoxyuridine (EdU) incorporation experiments there was a 1 hour pre-incubation of EdU in the ENR medium of the intact organoid cultures before dissociating the cells with trypLE. Cells were stained using Click-it kits for imaging and flow cytometry (Life Technologies).
(132) For phospho-STAT3 staining on organoids, prior to fixation with PFA4% (10 min 37° C.), the cells were stimulated as mechanically disrupted crypts (as for passaging) or as single cells (trypLE), for 20 minutes with 20 ng/ml IL-22 at 37° C. In some experiments, IL-22 stimulation was performed with single cell suspensions generated from freshly isolated crypts (not organoids). After obtaining a single cell suspension of stimulated and fixed cells, the samples were filtered (40 uM) and permeabilized with ice-cold (−20° C.) methanol. Fix/permed cells were rehydrated with PBS and thoroughly washed with PBS before staining, Staining with anti-phospho-STAT3, anti-GFP, and/or cell surface markers was performed for 30 minutes at 4° C. All flow cytometry was performed on a LSR II cytometer (BD Biosciences) using FACSDiva (BD Biosciences), and the data were analyzed with FlowJo software (Treestar).
(133) Organoid Measurement.
(134) Organoid numbers per well were counted by light microscopy to evaluate growth efficiency on culture day seven. For size evaluation, two-dimensional brightfield microscopy photographs were taken using a MetaMorph Widefield Live imaging system microscope with 5× (0.25 NA DRY) and 10× (0.3 NA DRY) Zeiss objectives, presenting the largest horizontal cross section of each organoid. The area and perimeter of each cross section were measured with MetaMorph Software.
(135) qPCR
(136) For quantitative (q)PCR, segments of small intestine or isolated crypts were harvested from euthanized mice and stored at −80° C. RNA was extracted from those tissues and stored at −20° C. Alternatively, RNA was isolated from organoids after in vitro culture. Reverse transcription-PCR was preformed with a Quanti-Tec reverse transcription kit (QIAGEN). Specific primers were obtained for real time PCR from Applied Biosystems as follows: Beta-actin: Mm01205647_g1; HPRT: Mm00446968_m1; Reg3β: Mm00440616_g1; Reg3γ: Mm00441127_m1; WNT3: Mm00437336_m1 and EGF: Mm00438696_m1; Rspo3: Mm00661105_m1; Axin2: Mm00443610_m1; Beta-catenin: Mm00483039_m1. qPCR was performed on a Step-One Plus (Applied Biosystems) with TaqMan Universal PCR Master Mix (Applied Biosystems). Relative amounts of mRNA were calculated by the comparative ΔC(t) method with beta-Actin or HPRT as housekeeping genes.
(137) Statistics and Software.
(138) All bars and error bars represent the means+SEM for the various groups. For the comparisons of two groups, a t-test or nonparametric U test was performed. ANOVA was utilized for comparisons of more than two groups. All statistics were calculated and display graphs were generated using Graphpad Prism. All experiments were performed at least twice with at least 3-5 mice in each group.
(139) Histopathologic Analysis of GVHD Target Organs.
(140) GVHD mice were sacrificed, and the small intestine, large intestine, andliver were removed, formalin-preserved, paraffin-embedded, sectioned, andstained with hematoxylin and eosin (H&E). Scoring was performed as previ-ously described (Petrovic et al., 2004).
(141) Tissue Analyses and Flow Cytometry. Lymphoid organs from GVHD mice were processed into single-cell suspen-sions, and lamina propria lymphocytes were isolated after dissociation of theepithelium and digestion in DNaseI (Roche) and Collagenase D (Roche). Surface staining was performed with the corresponding cocktail of antibodies, and an eBioscience Fixation/Permeabilization kit was used per the manufac-turer's protocol for intracellular staining. FACS for IL-22R (rat-anti-mouseIL-22R a antibody 496514, R&D Systems) included both surface and intracellular staining. Intracellular cytokine staining was performed with anti-IL-22 (1H8PWSR, eBioscience), anti-IFN-g (XMG1.2, BD PharMingen), or anti-TNF-a (MP6-XT22, BD PharMingen) after 5 hr of restimulation with BD GolgiPlug (1 ul/ml) and IL-23 (40 ng/ml) for IL-22 expression or phorbol-12-myris-tate-13-acetate (50 ng/ml) and ionomycin (500 ng/ml) for IFN-g and TNFexpression. IL-22 and IL-23 ELISA were performed per the manufacturer's protocol (BioLegend) on either homogenates from small and large intestines or on supernatants from intestines that were cultured at 37° C. overnight in RPMI with FBS. Immunohistochemistry, Immunofluorescence, TUNEL, LacZ, and ISC HistologyIntestines were harvested from normal mice, formalin-fixed, and stained with rat-anti-mouse IL-22R a antibody 496514 (R&D Systems) versus isotypecontrol and/or polyclonal rabbit anti-human lysozyme 3.2.1.17 (Dakocytoma-tion). Immunofluorescence secondary staining was performed with AF488 for IL-22R and AF568 for lysozyme. TUNEL assay was performed on formalin-fixed/paraffin-embedded tissue as described by Gavrieli et al. (1992). For Lgr5-LacZ transplants, 2.5 cm segments of ileum were obtained, and staining for presence of beta-galactosidase (LacZ) was performed as per Barker et al. (2007). In brief, small intestines were fixed in 1% formaldehyde, 0.2% glutaral-dehyde, and 0.02% NP40 in PBS and then incubated with b-galactosidases ubstrate. Tissues were then fixed again in 4% PFA in PBS and paraffin-embedded, and sections were counterstained with Nuclear Fast Red (Vector). For assessing ISCs in nonreporter mice, crypt base columnar intestinal stemcells were identified as reported by their morphology and their location at the crypt base between Paneth cells (Barker et al., 2007). Quantitative PCRReverse transcription-PCR was done with a QuantiTect reverse transcription kit (QIAGEN). For real-time PCR, specific primer and probe sets were obtained from Applied Biosystems as follows: Beta-actin: Mm01205647_g1, Reg3b:Mm00440616_g1, and Reg3g: Mm00441127_m1. PCR was done on ABI7500 (Applied Biosystems) with TaqMan Universal PCR Master Mix (AppliedBiosystems). Relative amounts of Reg3g and Reg3b mRNA were calculated by the comparative DC (t) method.
(142) Statistics. Bars and error bars represent the means+SEM, respectively, for the various groups. Survival data were analyzed with the Mantel-Cox log-rank test. For nonsurvival pointwise analyses, unpaired t test was used for comparisons between two experimental groups, or nonparametric Mann-Whitney U test was used for non-Gaussian distributions, and ANOVA was used for comparisons with more than two groups. Survival transplants were performed with 10-38 mice per group, and all other experiments were performed at least twice with at least six mice per group.
(143) Both MHC mismatched and minor histocompatibility antigen (miHA) mismatched transplants are performed to model both highly aggressive GVHD and clinically relevant transplant scenarios. Recipient mice are conditioned with lethal TBI as the pharmacokinetics of high dose chemotherapy are difficult to control experimentally. Recipients are then transplanted with T cell-depleted (TCD) marrow, which is supplemented with magnetic-bead-purified T cells to control for the effects of GVHD. Recipient mice are monitored post-transplant for clinical signs of GVHD (including weight, activity, posture, fur, and skin integrity) in accordance with MSKCC IACUC, and recipients are routinely sacrificed between 2-3 weeks post-transplant to evaluate T cell function and GVHD pathology. Statistical analyses will be performed with Sean Devlin, biostatistician for the MSKCC BMT service. In general, transplants will be performed with at least five mice per group, and all experiments will be repeated at least once. Comparisons between two groups will be made with nonparametric U tests. Experiments with more than two groups will be evaluated by ANOVA.
(144) Organoid culture: Crypts were isolated from the small and LI from intestinal epithelium and cultured in semisolid medium in the presence of stem cell growth factors (R-spondin1, EGF, noggin for SI; R-spondin1, EGF, noggin, HGF, and Wnt3a for LI). As each crypt contains a functional stem cell compartment with ISCs and supportive niche cells, crypts cultured ex vivo grow into organoids with crypt buds that recapitulate the in vivo intestinal organization with crypt-villus structures and central lumens (
Example II
(145) Host-derived IL-22 is important for limiting mortality and GVHD pathology post-transplant.
(146) Elimination of recipient IL-22 increases mortality post-transplant: Given the protective role reported for IL-22 in GI tissue damage, we began to assess the function of IL-22 post-BMT.
(147) IL-22 knock out (KO) recipients demonstrated increased mortality following both minor (
(148) IL-22 is expressed post-BMT and reduced during GVHD: We next identified expression of IL-22 within the GI tract (
(149) ISCs express IL-22R: Although host IL-22 deficiency increased GVHD (
(150) Immunohistochemistry (IHC) and immunofluorescence (IF) indicated IL-22R expression within intestinal crypts where the ISC niche is located (
(151) ISCs are lost in GVHD, and elimination of IL-22 leads to increased loss of ISCs during GVHD: To determine if ISCs could be targets of GVHD, we performed allo-BMT into Lgr5-LacZ reporter mice, which produce β-galactosidase downstream of Lgr5 to identify ISCs.sup.8. As evidence of ISC function, single Lgr5.sup.+ CBC cells are able to generate entire crypt structures in vitro and in vivo. Consistent with reported findings, we observed a dramatic reduction of ISCs during GVHD (
(152) Administration of IL-22 preserves ISCs in GVHD and reduces GVHD pathology: Given the reduction of IL-22 expression in GVHD and the exacerbated loss of ISCs in GVHD with IL-22 deficiency, we next examined the effect of IL-22 administration in GVHD. We found that daily administration of rmIL-22 (4 ug IP starting day +7) led to decreased GVHD pathology in recipient SI, LI, and liver three weeks post-BMT (
(153) Administration of IL-22 augments ISC function without improving the ISC niche: Given the loss of ISCs we observed in GVHD, we sought to evaluate the Paneth cells that constitute the ISC niche in normal epithelial maintenance. Similar to what was reported in aggressive MHC-mismatched GVHD, we observed a reduction in Paneth cells in a minor mismatch GVHD model (
(154) Summary: Our preliminary data reveal reciprocal networks between epithelium and the immune system, where GI tissue damage leads to induction of IL-23, which can stimulate IL-22 production by ILCs. This IL-22 protects the epithelium and the ISC compartment from inflammatory tissue damage. However, the IL-22-producing ILCs necessary for promoting ISC function are lost during GVHD. This indicates that GVHD leads to damage of the ISC compartment and its ability to mediate epithelial regeneration after tissue damage. This also suggests a potential therapeutic approach for augmenting ISC function in GVHD by replacing the lost IL-22. However, effective translation of these findings requires a detailed understanding of the normal intestinal homeostasis post-transplant, the damage inflicted upon ISCs directly and upon their Paneth cell niche, and the effect of IL-22 on ISCs and their progenitors.
Example III
(155) Daily IP administration with rIL-22.
(156) A clinically modeled LP into C57BL/6 (B6) minor antigen mismatched model with T cell-depleted marrow and MACS-purified T cells transplanted into lethally irradiated mice. Recipients were treated daily with PBS or 4 ug murine recombinant (r)IL-22 delivered via intraperitoneal (IP) injection starting day 7 post-HCT. This schedule was based on the results of rIL-22 pharmacokinetics tested in untransplanted mice.
(157) Daily IP administration with rIL-22 led to decreased GVHD pathology in recipient small intestine, large intestine, and liver three weeks post-HCT (
Example IV
(158) IL-22 administration effects on the intestinal stem cells (ISC) compartment.
(159) LP into B6 allo-HCT using Lgr5-LacZ ISC reporter mice. Recipients treated with rIL-22 demonstrated increased numbers of Lgr5+ ISC three weeks post-HCT during active GVHD with no immunosuppression (
Example V
(160) IL-22 administration to B6 into BALB/c tumor challenge recipients did not limit GVL.
(161) IL-22R expression was not found in hematopoietic cells. Therefore, luciferase+A20 tumor cell bioluminescence was monitored to follow the GVT effect mediated by B6 T cells transplanted into BALB/c tumor challenge recipients treated with rIL-22.
Example VI
(162) IL-22 administration improved peripheral T cell reconstitution even during active GVHD.
(163) FVB MHC-mismatched transplant bone marrow was transplanted into BALB/c with Rag2-GFP marrow and WT T cells. IL-22 administration as described herein, increased the development of donor marrow-derived CD4 and CD8+ thymic emigrants four weeks post-HCT (
Example VII
(164) Uses of IL-22.sup.+ lactobacilli of the present inventions and effects of IL-22.sup.+ lactobacilli on GVHD and GI tissue damage post-HCT.
(165) This Example shows results of endogenous loss of IL-22 production in GVHD (section A) along with an reduction of GVHD tissue damage by administration of IL-22.sup.+ lactobacilli. As shown in section B. below, Lactobacillus administration was shown to reduce experimental GVHD.
(166) Lactobacillus paracasei is a normal constituent of human GI flora. Therefore the inventors contemplated the use of Lactobacillus paracasei to deliver therapeutic doses of exogenous IL-22 for providing additional therapeutic benefits.
(167) A. Experimental Results of HCT in Mice Expressing Reduced Endogenous IL-22.
(168) IL-22−/− KO recipients of HCT demonstrated increased mortality following both minor (
(169) Expression of IL-22 was found within the GI tract (
(170) Although host IL-22 deficiency increased GVHD (
(171) Immunohistochemistry (IHC) and immunofluorescence (IF) indicated IL-22R expression within intestinal crypts where the ISC niche is located (
(172) Therefore, GI damage led to induction of IL-23. IL-23 in turn can stimulate IL-22 production by ILC. This endogenous IL-22 protected the epithelium and the stem/progenitor cell compartment from inflammatory tissue damage. However, IL-22-producing ILC necessary for limiting tissue damage were lost during GVHD. As shown herein, administration of rIL-22 post HCT by intraperitoneal injection (for example, 4 ug/mouse daily) reversed the effects of ILC depletion and loss of IL-22 in GVHD pathology within the intestines as well as reduce apoptosis within intestinal crypts where the ISC/progenitor compartment is located (
(173) B. Result of IL22+ Lactobacilli Treatment of GVHD.
(174) As described herein, after discovering that IL-22 deficiency lead to increased GVHD (
(175) In contrast, mice receiving lacto-22s or lacto-22a did not have significantly different mortality compared to mice transplanted without T cells. Furthermore, recipients of lacto-22s had significantly reduced clinical scores of GVHD, an assessment encompassing weight, fur quality, skin integrity, posture, and activity. While the change in weights of mice post-HCT can serve as a surrogate measure for GI GVHD, the systemic nature of these findings suggest that GI protection may be central to preventing systemic disease from GVHD.
(176) T cell depleted MHC matched allo-HCT was done as described above and mice were gavaged daily with lacto-WT, lacto-22s, and lacto-22a.
Example VIII
(177) Using clinically modeled LP.fwdarw.C57BL/6 (B6) minor antigen-mismatched HSCT (H-2.sup.b.fwdarw.H-2.sup.b), we found that daily treatment with recombinant murine (rm) IL-22 (4 ug, intraperitoneal injection) starting day seven after transplant led to reduced intestinal pathology from GVHD without altering alloreactive immunity. Both overall GVHD pathology and epithelial apoptosis scores were significantly lower three weeks post-BMT in rmIL-22-treated mice with GVHD compared to PBS-treated controls (p<0.001). We observed that mice treated with rmIL-22 (and no pharmacologic immunosuppression) had increased numbers of Lgr5+ISCs and significantly greater ISC proliferation (p<0.01). This was not due to IL-22-dependent changes in the ISC niche, as Paneth cell numbers, Paneth cell-derived growth factors (EGF, Wnt3), and stroma-derived growth factors (Rspo3) were all unchanged after IL-22 administration. However, the antimicrobial proteins Reg3β and Reg3γ were both upregulated by qPCR in small intestine (SI) of rmIL-22-treated mice (p<0.01 and p<0.001 respectively), although this did not result in consistent changes in the gut microbial flora.
(178) To evaluate direct effects on epithelial regeneration, we performed intestinal organoid culture assays in the presence of IL-22. Organoids generated from SI and large intestine (LI) crypts of wild-type B6 mice demonstrated substantially increased size after seven days of culture with IL-22 (p<0.001, SI,
(179) To investigate the translational potential for use in humans, we tested a human IL-22 dimer molecule (F-652, Evive Biotechnology (Shanghai) Ltd.) on mouse intestinal crypts and found that F-652 significantly increased the size of SI and LI organoids. Using the LP.fwdarw.B6 allo-HSCT model described above, we found that every other day subcutaneous (SQ) treatment with 100 ug/kg F-652 starting day seven post-BMT led to significant improvement in both clinical GVHD score (P<0.0001) and survival (p<0.05,
(180) IL-22 and innate lymphoid cells can bridge immune function and tissue regeneration by acting directly on epithelial stem cells. IL-22 and F-652 therapy may represent a novel approach to promote intestinal recovery in patients with GVHD without increasing post-transplant immunodeficiency.
(181) In summary, IL-22 administration was discovered to reduce intestinal pathology, improve ISC recovery, and promote donor marrow-derived T cell development during GVHD. Surprisingly, IL-22 administration did not impair GVL. These results suggest that post-transplant IL-22 administration represents a novel strategy to protect intestinal epithelium and improve immune reconstitution after allo-HCT.
(182) All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described compositions and methods of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in medicine, diagnostics, immunology, cell biology, molecular biology or related fields are intended to be within the scope of the present invention and the following Claims.
(183) The following references are herein incorporated by reference in their entirety:
(184) 1. Jenq, R. R. & van den Brink, M. R. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 10, 213-221. 2. CIBMTR Newsletter. 13 (2007). 3. Hill, G. R. & Ferrara, J. L. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95, 2754-2759 (2000). 4. Wingard, J. R. et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 29, 2230-2239. 5. Shlomchik, W. D. Graft-versus-host disease. Nat Rev Immunol 7, 340-352 (2007). 6. Takashima, S. et al. The Wnt agonist R-spondin regulates systemic graft-versus-host disease by protecting intestinal stem cells. JExp Med 208, 285-294 (2011). 7. Sale, G. E. Does graft-versus-host disease attack epithelial stem cells? Mol Med Today 2, 114-119 (1996). 8. Barker, N. et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003-1007 (2007). 9. Sato, T. et al. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469, 415-418 (2010). 10. Carmon, K. S., Lin, Q., Gong, X., Thomas, A. & Liu, Q. LGR5 interacts and cointernalizes with Wnt receptors to modulate Wnt/beta-catenin signaling. Mol Cell Biol 32, 2054-2064 (2012). 11. Glinka, A. et al. LGR4 and LGR5 are R-spondin receptors mediating Wnt/beta-catenin and Wnt/PCP signalling. EMBO Rep 12, 1055-1061 (2011). 12. de Lau, W. et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 476, 293-297 (2011). 13. Simons, B. D. & Clevers, H. Stem cell self-renewal in intestinal crypt. Exp Cell Res (2011). 14. Barker, N., van Oudenaarden, A. & Clevers, H. Identifying the stem cell of the intestinal crypt: strategies and pitfalls. Cell Stem Cell 11, 452-460 (2012). 15. Eriguchi, Y. et al. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of alpha-defensins. Blood 120, 223-231 (2012). 16. Levine, J. E. et al. Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. Blood 122, 1505-1509 (2013). 17. Hanash, A. M. et al. Interleukin-22 Protects Intestinal Stem Cells from Immune-Mediated Tissue Damage and Regulates Sensitivity to Graft versus Host Disease. Immunity 37, 339-350 (2012). 18. Clayburgh, D. R., Shen, L. & Turner, J. R. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 84, 282-291 (2004). 19. Kappel, L. W. et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 113, 945-952 (2009). 20. Nagalakshmi, M. L., Rascle, A., Zurawski, S., Menon, S. & de Waal Malefyt, R. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. International Immunopharmacology 4, 679-691 (2004). 21. Pickert, G. et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 206, 1465-1472 (2009). 22. Zenewicz, L. A. et al. Innate and Adaptive Interleukin-22 Protects Mice from Inflammatory Bowel Disease. 29, 947-957 (2008). 23. Zenewicz, L. A. et al. Interleukin-22 but Not Interleukin-17 Provides Protection to Hepatocytes during Acute Liver Inflammation. 27, 647-659 (2007). 24. Witte, E., Witte, K., Warszawska, K., Sabat, R. & Wolk, K. Interleukin-22: A cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev (2010). 25. Sonnenberg, G. F., Fouser, L. A. & Artis, D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 12, 383-390. 26. Wolk, K. et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36, 1309-1323 (2006). 27. Sekikawa, A. et al. Involvement of the IL-22/REG Ialpha axis in ulcerative colitis. Lab Invest 90, 496-505. 28. Zheng, Y. et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 14, 282-289 (2008). 29. Aujla, S. J. et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. NatMed 14, 275-281 (2008). 30. Das, R., Chen, X., Komorowski, R., Hessner, M. J. & Drobyski, W. R. Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease. Blood 113, 2352-2362 (2009). 31. Cella, M. et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457, 722-725 (2009). 32. Kreymborg, K. et al. IL-22 Is Expressed by Th17 Cells in an IL-23-Dependent Fashion, but Not Required for the Development of Autoimmune Encephalomyelitis. J Immunol 179, 8098-8104 (2007). 33. Sonnenberg, G. F., Monticelli, L. A., Elloso, M. M., Fouser, L. A. & Artis, D. CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity 34, 122-134 (2011). 34. Zheng, Y. et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445, 648-651 (2007). 35. Medema, J. P. & Vermeulen, L. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 474, 318-326. 36. Hua, G. et al. Crypt base columnar stem cells in small intestines of mice are radioresistant. Gastroenterology 143, 1266-1276 (2012). 37. Wang, F. et al. Isolation and characterization of intestinal stem cells based on surface marker combinations and colony-formation assay. Gastroenterology 145, 383-395 e381-321 (2013). 38. Yui, S. et al. Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5(+) stem cell. Nat Med 18, 618-623 (2012). 39. Sato, T. et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262-265 (2009). 40. Gerbitz A, Schultz M, Wilke A, et al. Probiotic effects on experimental graft-versus-host disease: let them eat yogurt [Research Support, Non-U.S. Gov't]. Blood. 2004; 103(11):4365-4367. 41. Jenq R R, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. The Journal of experimental medicine. 2012; 209(5):903-911. 42. Dimartino J F, Cleary M L. Mll rearrangements in haematological malignancies: lessons from clinical and biological studies. Br J Haematol. 1999; 106(3):614-626. 43. Stubbs M C, Kim Y M, Krivtsov A V, et al. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2008; 22(1):66-77. 44. Krivtsov A V, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9 [Research Support, Non-U.S. Gov't]. Nature. 2006; 442(7104):818-822. 45. Sanos, S. L. & Diefenbach, A. Innate lymphoid cells: from border protection to the initiation of inflammatory diseases. Immunol Cell Biol 91, 215-224 (2013). 46. Peery, A. F. et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143, 1179-1187 (2012). 47. Metcalfe, C., Kljavin, N. M., Ybarra, R. & de Sauvage, F. J. Lgr5+ stem cells are indispensable for radiation-induced intestinal regeneration. Cell Stem Cell 14, 149-159 (2014). 48. Ritsma, L. et al. Intestinal crypt homeostasis revealed at single-stem-cell level by in vivo live imaging. Nature 507, 362-365 (2014). 49. Morris, S. A. et al. Dissecting Engineered Cell Types and Enhancing Cell Fate Conversion via CellNet. Cell 158, 889-902 (2014). 50. Sabat, R., Ouyang, W. & Wolk, K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 13, 21-38 (2014). 51. Sawa, S. et al. RORgammat+innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nat Immunol 12, 320-326 (2011). 52. Longman, R. S. et al. CX3CR1+ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. J Exp Med 211, 1571-1583 (2014). 53. Spits, H. et al. Innate lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol 13, 145-149 (2013). 54. Munneke, J. M. et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. Blood 124, 812-821 (2014). 55. Pearson, C., Uhlig, H. H. & Powrie, F. Lymphoid microenvironments and innate lymphoid cells in the gut. Trends Immunol 33, 289-296 (2012). 56. Zhou, W. J., Geng, Z. H., Spence, J. R. & Geng, J. G. Induction of intestinal stem cells by R-spondin 1 and Slit2 augments chemoradioprotection. Nature 501, 107-111 (2013). 57. Choi, S.-M. et al. Innate Stat3-mediated induction of the antimicrobial protein Reg3γ is required for host defense against MRSA pneumonia. J Exp Med 210, 551-561 (2013). 58. Matthews, J. R., Sansom, O. J. & Clarke, A. R. Absolute requirement for STAT3 function in small-intestine crypt stem cell survival. Cell Death Differ 18, 1934-1943 (2011). 59. Ferrara, J. L., Levine, J. E., Reddy, P. & Holler, E. Graft-versus-host disease. Lancet 373, 1550-1561 (2009). 60. Blazar, B. R., Murphy, W. J. & Abedi, M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 12, 443-458 (2012). 61. Schroeder, M. A. & DiPersio, J. F. Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech 4, 318-333 (2011). 62. Kolls, J. K., McCray, P. B., Jr. & Chan, Y. R. Cytokine-mediated regulation of antimicrobial proteins. Nat Rev Immunol 8, 829-835 (2008). 63. Walker, C. R. et al. Intestinal intraepithelial lymphocyte-enterocyte crosstalk regulates production of bactericidal angiogenin 4 by Paneth cells upon microbial challenge. PLoS One 8, e84553 (2013). 64. Kabiri, Z. et al. Stroma provides an intestinal stem cell niche in the absence of epithelial Wnts. Development 141, 2206-2215 (2014). 65. Zhao, K. et al. Interleukin-22 Aggravates Murine Acute Graft-Versus-Host Disease by Expanding Effector T Cell and Reducing Regulatory T Cell. J Interferon Cytokine Res 34, 707-715 (2014).